Conference Proceedings

REAL WORLD EVIDENCE (RWE) ON LONG-TERM PERSISTENCE OF FINGOLIMOD IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN AUSTRALIA

Robert Walker, Mark Schulz, Birendra Arora, Eric Chung, Prabhjot Juneja, Stephane Verhaeghe, Tim Spelman, Simon Broadley

Journal of Neurology Neurosurgery & Psychiatry | BMJ PUBLISHING GROUP | Published : 2018

Abstract

IntroductionThis study aimed to examine and compare patient persistence of fingolimod to all reimbursed disease modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) in Australia.MethodThe Pharmaceutical Benefits Scheme (PBS) 10% sample supplied by the Department of Human Services was used in this study. Eligible patients must have received a script for a reimbursed DMT for RRMS between September 2011 and February 2016. Patient demographics were summarised using mean and standard deviation or frequency percentage. Persistence was defined as a patient that remained on a DMT with a gap in scripts of no longer than 4 months. Individual patients could be included multiple ..

View full abstract